Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe palmoplantar pustulosis
NCT04015518Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of spesolimab in palmoplantar pustulosis (PPP), sponsored by Boehringer Ingelheim. Started Jul 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04015518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015518.